Company Overview and News

to your dashboard

Headline News

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

8h seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-1)

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials

2017-11-10 seekingalpha
CRSP's update on their pipeline is encouraging - IND on track for 2017, first company in the CRISPR-Cas9 clinical space. (25-0)

Editas Medicine's (EDIT) CEO Katrine Bosley on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon and welcome to Editas Medicine’s Third Quarter 2017 Financial Results and Update Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at Editas Medicine’s request. I would now like to turn the call over to the Editas Medicine team. Please proceed. (19-0)

What's in the Cards for Adverum (ADVM) This Earnings Season?

2017-11-04 zacks
Adverum Biotechnologies, Inc. (ADVM - Free Report) is expected to report third-quarter 2017 results on Nov 14. (75-0)

Calyxt Jumping Into A Crowded Space

2017-10-31 seekingalpha
Calyxt is using the excitement regarding cutting edge technologies in the genome editing space to support its product pipeline. (49-0)

Catabasis And Capricor: 2 Solid Buys In DMD Treatment

2017-10-23 seekingalpha
Duchenne Muscular Dystrophy is the most common fatal genetic disorder in childhood, and currently has very poor treatment options for sufferers. (65-8)

Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack

2017-10-23 seekingalpha
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-1)

Protein Tx Startup Cofounded by George Church Raises $2.1M in Seed Funding

2017-09-29 genengnews
Precision Medicine Is Maintaining a Learning Cycle That Connects Data Collection, Evidence-Based Treatment, and Outcome Analysis (29-0)

Feng Zhang Joins Society for Science & the Public Board of Trustees

2017-09-28 prnewswire
WASHINGTON, Sept. 28, 2017 /PRNewswire-USNewswire/ -- The Society for Science & the Public is excited to share that noted scientist, Feng Zhang, has joined the Society's Board of Trustees.  Zhang is a core member of the Broad Institute of MIT and Harvard, an Investigator at the McGovern Institute for Brain Research, the James and Patricia Poitras Professor of Neuroscience at MIT, an associate professor in the departments of Brain and Cognitive Sciences and Biological Engineering at MIT, and a New York Stem Cell Foundation-Robertson Investigator. (14-1)

Gene Editing Could Modify And Cure Disease: CRISPR Vs. TALENs

2017-09-21 seekingalpha
During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure. The ability to directly edit living cells has brought gene therapy and precision medicine into a new era, one that will accelerate the pace of scientific research and increase the value of molecular diagnostic tests. (25-1)

CRISPR Field Patent Fight Extended: Focus On Science, Time Frames, Risks

2017-09-21 seekingalpha
CRISPR Therapeutics is currently under appreciated considering they are the closest company to beginning clinical trials. (101-2)

Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health

2017-09-18 prnewswire
- Mike Bonney, former CEO of Cubist Pharmaceuticals, to lead Kaleido through its next phase of growth - Broad pipeline of novel chemistries to optimize the human microbiome's functions - $65 million in funds raised since company's founding in 2015 (26-0)

Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

2017-08-14 zacks
Editas Medicine, Inc. (EDIT - Free Report) was a big mover last session, as its shares rose over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $15.45 to $18.86 in the past one-month time frame.

This Technology Could Make You Rich -- and Change the World As We Know It

2017-08-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-3)

CUSIP: 28106W103